AONC

American Oncology Network Inc.

American Oncology Network Inc. (AONC) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B-); its weakest is Profitability (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C
Factor Score 2.4 / 5.0
Growth
B-
Factor Score 3.0 / 5.0
Profitability
D+
Factor Score 1.7 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA 238.1
Rev Growth YoY 51.4%
Gross Margin 6.8%
Price Return 3M 11.1%
Price Return 12M N/A
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 0.2
ROE -30.2%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C (2.4) B- (3.0) D+ (1.7) C (2.4) C- (1.9) C (2.3)
2026-08-04 C (2.5) B- (3.0) D+ (1.7) C (2.4) C- (1.9) C (2.3)
2026-08-03 C (2.4) C+ (2.6) C (2.2) C (2.4) C- (2.0) C (2.3)
2026-08-02 C (2.5) C+ (2.6) C- (2.1) C (2.4) C- (1.9) C (2.3)